A pediatric case of dupilumab-induced pustular psoriasis
Aim: Dupilumab is a novel treatment agent for moderate to severe atopic dermatitis (AD) with few adverse effects. Drug-induced psoriasiform lesions are rare.Methods: We report a 4-year-old boy with AD who developed pustular psoriasis during treatment with dupilumab.Results: Pustular psoriasis appear...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aim: Dupilumab is a novel treatment agent for moderate to severe atopic dermatitis (AD) with few adverse effects. Drug-induced psoriasiform lesions are rare.Methods: We report a 4-year-old boy with AD who developed pustular psoriasis during treatment with dupilumab.Results: Pustular psoriasis appeared within 1 week of treatment and worsened in the second week. After stopping dupilumab administration, topical corticosteroids (desonide and mometasone furoate creams) and oral desloratadine without relief. Pustular psoriasis was confirmed by pathological examination, and thiamphenicol was administered. After 2 weeks of treatment, the lesions nearly resolved without recurrence in 1-year follow-up.Conclusions: Dupilumab-induced pustular psoriasis is rare in children. |
|---|---|
| Item Description: | 10.1080/09546634.2024.2333016 1471-1753 0954-6634 |